A recent systematic review has indicated the safety and efficacy of .19 mg fluocinolone acetonide sustained-release intravitreal implants for treating non-infectious uveitis affecting the posterior segment of the eye (NIU-PS) in real-world scenarios.1
The standard treatment method for NIU is corticosteroids; however, local and/or systemic side effects can constrain their use. Immunosuppressive agents have become an increasingly common method of managing ocular inflammation caused by NIU. Many of these treatments, however, come with the risk of adverse effects.2
Fluocinolone acetonide was initially approved in 2019 for the treatment of recurrent NIU-PS in Europe. Real world data have emerged since then to improve awareness of patient outcomes in everyday clinical practice.1
“With this systematic review of real-world…